it depends. There is lots of talk of monepantel being a platform therapy for a host of neurodegenerative disorders. If you only want it as a solution for MND and it works that’s all you need to know. If the opportunity is beyond MND it might be good to know. Perhaps we will get some insights at the agm today
Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-161
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $141.2K | 801.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 537419 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 140000 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |